CRISPR Cancer Therapy Breakthroughs: 2026 Clinical Trial Results
By Dr. Sarah Mitchell, Respiratory Equipment Specialist · Published 2026-02-12 · 11 min read
CRISPR-edited CAR-T cells and base editing therapies are achieving remission rates above 80% in late-stage lung and blood cancers. Inside the latest research.
CRISPR Goes Mainstream in Oncology
After Casgevy's 2023 FDA approval for sickle cell disease, CRISPR-Cas9 gene editing has moved aggressively into oncology. 2026 trials are reporting durable remissions for previously untreatable cancers.
Headline Trials
- CTX130 (allogeneic CAR-T) — 70% complete response in relapsed T-cell lymphoma
- Verve Therapeutics base editing — single-dose cholesterol lowering, with cancer applications in pipeline
- Intellia NTLA-2002 — in vivo CRISPR for hereditary cancer syndromes
Why This Matters for Lung Cancer
Non-small cell lung cancer (NSCLC) patients with EGFR and KRAS mutations are now being enrolled in CRISPR-edited TIL (tumor-infiltrating lymphocyte) trials, with early-phase data showing 40% objective response in chemo-refractory disease.
What Patients Should Know
CRISPR therapies remain investigational for most solid tumors. Eligible patients should ask oncologists about NCI-MATCH and TAPUR trial networks.
For patients managing post-treatment respiratory symptoms, home oxygen concentrators and portable units provide essential support during recovery.